Exelixis Inc (NAS:EXEL)
$ 36.115 0.265 (0.74%) Market Cap: 10.31 Bil Enterprise Value: 9.21 Bil PE Ratio: 23.15 PB Ratio: 4.54 GF Score: 91/100

Exelixis Inc at RBC Global Healthcare Conference Transcript

May 19, 2020 / 06:30PM GMT
Release Date Price: $24.88 (-3.15%)
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research

Hi. My name is Kennen MacKay. I'm one of the senior biotechnology analysts here at RBC, and it's my great pleasure to kick off this next session with Exelixis. And from Exelixis. I'm joined by Dr. Mike Morrissey, the President and Chief Executive Officer.

Mike, thanks so much for joining this afternoon.

Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director

How you're doing today? Glad to be on the call with you virtually, not the same as being in New York, but not bad either. So hope you're doing good.

Questions & Answers

Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research

Thanks, Mike. Likewise. So maybe it seems like Exelixis is really firing on all cylinders now, both commercially and clinically with some really very impressive data sets out recently. And I'd love to get to those. But first, cabo really surprised to the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot